logo-loader
viewBard1 Life Sciences Ltd

BARD1 Life Sciences signs agreement to develop custom research assay

The company’s proprietary platform, BARD1, is based on novel tumour markers with potential diagnostic applications.

BARD1-Ovarian test
BARD1-Ovarian test is being developed for early detection of ovarian cancer

BARD1 Life Sciences Limited (ASX:BD1) has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system.

The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using Thermo Fisher’a ProcartaPlex® Technology for BARD1’s research use.

The first application of the ProcartaPlex® Technology is to the BARD1-Ovarian test that BARD1 plans to develop for detection of ovarian cancer.

The custom research assay development project will commence this month and is expected to take about nine months.

Evaluating the accuracy of the BARD1-Ovarian test

If the development project is successful, BARD1 and Thermo Fisher will then discuss the potential for Thermo Fisher to supply research autoantibody kits to BARD1 for its use in research studies.

BARD1 chief executive officer Dr Leearne Hinch said: “We are pleased to work with such an experienced partner.

“The development of a RUO BARD1 autoantibody assay for use on Luminex® instrumentation will be an important milestone for the company, enabling us to initiate clinical testing to evaluate the accuracy of the new multiplex BARD1-Ovarian test for early detection of ovarian cancer in early 2019.”

READ: BARD1 Life Sciences secures Israeli patent for unique lung cancer test

BARD1 was recently issued a patent in Israel for detecting BARD1 isoforms (proteins) in lung and colorectal cancer.

The company’s proprietary technology platform, BARD1, is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.

BARD1’s patent portfolio comprises five patent families with multiple granted and pending patents across key markets including the US, Europe and Japan.

Quick facts: Bard1 Life Sciences Ltd

Price: 0.034 AUD

ASX:BD1
Market: ASX
Market Cap: $46.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls Bears & Brokers: Martin Place Securities Barry Dawes on market highs...

Martin Place Securities executive chairman Barry Dawes speaks to Proactive about the highs and lows of the markets, and takes us through his bulls and bears outlook. Dawes says there are record highs in equity markets, bond markets are turning down again, currencies are showing trendless...

7 hours, 43 minutes ago

2 min read